Present Status of Anticoagulation Treatment in Japanese Patients With Atrial Fibrillation : A Report From the J-RHYTHM Registry

Access this Article

Search this Article



<b><i>Background:</i></b> Underuse and an inadequate range for the international normalized ratio (INR) for warfarin use are still problems in the management of the patients with atrial fibrillation (AF) in Japan. <b><i>Methods and Results:</i></b> From January to July 2009, a total of 7,937 AF patients [5,468 men (68.6±10.0 years) and 2,469 women (72.2±9.0 years)] were registered from 158 institutions for the J-RHYTHM Registry. Overall, 34.2% of the patients were over the age of 75. The associated cardiovascular diagnoses were hypertension in 59.1%, coronary artery disease in 10.1%, cardiomyopathy in 8.3%, valvular heart disease in 13.7% and artificial cardiac valves in 3.1% of the patients. The type of AF was paroxysmal in 37.1%, persistent in 14.4%, and permanent in 48.5%. Overall, 87.3% of patients were taking warfarin (2.9±1.2mg/day), of whom 66.0% had an INR between 1.6 and 2.6, and 35.4% were in the INR range from 2.0 to 3.0 at the time of registration. Aspirin was prescribed in 22.3% of cases. The CHADS2 score was 0 in 15.7% of patients, 1 in 34.0%, and ≥2 in 50.3%. <b><i>Conclusions:</i></b> At present, warfarin is used extensively in patients with AF whose stroke risk is relatively low (ie, in Japan) and half of them had CHADS2 scores of 0 to 1 (UMIN Clinical Trials Registry UMIN000001569). (<i>Circ J</i> 2011; <b>75:</b> 1328-1333)<br>


  • Circulation Journal

    Circulation Journal 75(6), 1328-1333, 2011-05-25

    The Japanese Circulation Society

References:  24

Cited by:  19


  • NII Article ID (NAID)
  • Text Lang
  • Article Type
    Journal Article
  • ISSN
  • Data Source
    CJP  CJPref  J-STAGE 
Page Top